Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous T cells encoding a chimeric antigen receptor targeting human B cell maturation antigen
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous T cells encoding a chimeric antigen receptor (CAR) targeting human B-cell maturation antigen (BCMA) represent a class of personalized cell therapies primarily used to treat multiple myeloma. The process involves collecting a patient's T cells, genetically modifying them (often using a lentiviral or retroviral vector) to express a CAR specific to BCMA, and then expanding and re-infusing them into the patient. BCMA is a cell surface receptor highly and selectively expressed on mature B lymphocytes and plasma cells, making it an ideal target for multiple myeloma. Once infused, these CAR-T cells recognize and eliminate BCMA-positive malignant cells. Approved therapies in this category include idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), while others like Novartis's PHE885 are in clinical development.
- Brand names
- AbecmaCarvykti
- Other names
- BCMA CAR-Tanti-BCMA CAR-TBCMA-targeted CAR-T cell therapyidecabtagene vicleucelciltacabtagene autoleucel
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on autologous T cells encoding a chimeric antigen receptor targeting human B cell maturation antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous T cells encoding a chimeric antigen receptor targeting human B cell maturation antigen.